Clinical Trial

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Inhaled XQ-001 in Healthy Subjects

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The primary study objective is to evaluate the safety and tolerability of XQ-001 for inhalation after single and multiple nebulized inhalation administration in healthy Chinese adult subjects.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-08.
Trial Details
NCT Number NCT06918366
Lead Sponsor Brilliant Inspiration Biotherapeutics
Conditions Healthy
Enrollment 58 participants
Start Date 2024-08-01
Primary Completion 2025-03-31 (estimated)
Study Completion 2025-05-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-10